Literature DB >> 18685492

Relevance of immunocytochemistry on thin-layer cytology in thyroid lesions suspicious for medullary carcinoma: a case-control study.

Esther Diana Rossi1, Marco Raffaelli, Antonino Mulè, Gian Franco Zannoni, Alfredo Pontecorvi, Giuseppe Santeusanio, Corrado Minimo, Guido Fadda.   

Abstract

BACKGROUND: Fine needle aspiration cytology represents the most important tool in the diagnosis of thyroid nodules, mostly in discriminating malignant from benign lesions. The diagnosis of medullary thyroid carcinoma (MTC) may present some problems related to its deceptive morphologic picture. This diagnosis may be supported by immunocytochemistry (ICC), which may be difficult to carry out on the conventional smears.
DESIGN: The diagnostic efficacy of ICC for the diagnosis of MTC with respect to other thyroid neoplasms on slides processed by thin-layer cytology (TLC) is evaluated. PATIENTS: In the period between January 2002 and December 2005, 8,200 FNAB were processed. ICC on TLC slides was required in 33 cases. Conventional smears were fixed in ethanol, whereas TLC slides were processed with the Thin Prep 2000 method. All slides were then stained with Papanicolaou. In all cases where MTC was morphologically suspected, ICC for calcitonin, monoclonal carcinoembryonic antigen, and thyroglobulin was carried out only on TLC slides.
RESULTS: Thirty-three thyroid cytologic cases had ICC on the TLC slides, including 22 follicular proliferations and 11 malignant lesions. The application of ICC on TLC was conclusive in 32 cases and inconclusive in 1 case. Twenty cases underwent surgery. No false-positive and false-negative cases were found. Sensitivity and specificity were 100%, and the overall diagnostic accuracy was 100%.
CONCLUSIONS: ICC can be successfully applied on TLC slides. The combined results of morphology and a small immunopanel including thyroglobulin, calcitonin, and carcinoembryonic antigen yields a 100% diagnostic efficacy for MTC. CONDENSED ABSTRACT: Fine needle aspiration cytology is an excellent technique for diagnosing malignant neoplasms of the thyroid, especially those derived from the follicular cells. A correct preoperative diagnosis of C-cell-derived tumors (MTC), which is essential for both the surgical approach to the primary tumor and the management of the patient, should rely not only on the morphologic picture but also on the immunocytochemical yielding using an immunopanel, which is particularly satisfactory on the TLC slides.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18685492     DOI: 10.1097/PAI.0b013e3181690ca3

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  5 in total

1.  True mixed medullary papillary carcinoma of the thyroid: a case report with low blood calcitonin levels.

Authors:  Pablo Zoroquiain; Javiera Torres; Ignacio Goñi; Lizzet Fernández; Antonieta Solar
Journal:  Endocr Pathol       Date:  2012-09       Impact factor: 3.943

Review 2.  Pitfalls in Thyroid Cytopathology.

Authors:  Esther Diana Rossi; Adebowale J Adeniran; William C Faquin
Journal:  Surg Pathol Clin       Date:  2019-12

3.  Application of liquid-based cytology to fine-needle aspiration biopsies of the thyroid gland.

Authors:  Esther Diana Rossi; Gian Franco Zannoni; Stefania Moncelsi; Egidio Stigliano; Giuseppe Santeusanio; Celestino Pio Lombardi; Alfredo Pontecorvi; Guido Fadda
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-16       Impact factor: 5.555

4.  Diagnostic validity of fine-needle capillary cytology in palpable tumours at the Oncology Institute of Peru.

Authors:  Milagros Abad-Licham; Jose Galvez-Olortegui; Juan Astigueta; Juan Díaz-Plasencia
Journal:  Ecancermedicalscience       Date:  2018-02-01

5.  Calcitonin measurement in fine-needle aspirate washouts vs. cytologic examination for diagnosis of primary or metastatic medullary thyroid carcinoma.

Authors:  C de Crea; M Raffaelli; D Maccora; C Carrozza; G Canu; G Fadda; R Bellantone; C P Lombardi
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-12       Impact factor: 2.124

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.